Please assess the completion status of the following clinical trial:

Trial Title: 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Psoriatic Arthritis (PsA) classified by ClASsification criteria for Psoriatic ARthritis (CASPAR) criteria.~* Rheumatoid factor and anti-cyclic citrullinated peptide (CCP) antibodies negative.~* Diagnosis of active plaque psoriasis or nail changes consistent with psoriasis.~* Inadequate control of symptoms with NSAID.~* Other protocol-defined inclusion criteria do apply.~Exclusion Criteria:~* Chest X-ray or chest magnetic resonance imaging (MRI) with evidence of ongoing infectious or malignant process.~* Subjects taking high potency opioid analgesics.~* Previous exposure to secukinumab or other biologic drug directly targeting interleukin-17 (IL-17) or IL-17 receptor.~* Ongoing use of prohibited psoriasis treatments / medications.~* Subjects who have ever received biologic immunomodulating agents except for those targeting TNFα.~* Previous treatment with any cell-depleting therapies.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab 150 mg (Type: EXPERIMENTAL): Secukinumab 150 mg s.c. with loading: Secukinumab 150 mg at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator
- Secukinumab 150 mg No load (Type: EXPERIMENTAL): Secukinumab 150 mg s.c. without loading: Secukinumab 150 mg at baseline, followed by dosing every four weeks starting at Week 4, with Placebo at Weeks 1, 2 and 3. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to Secukinumab at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4 until Week 16/24, depending on patients responder status. From Week 16/24, patients were switched to Secukinumab 150 mg every four weeks. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator

Based on this trial design, predict the completion outcome and termination type (if applicable).